BiOasis Technologies | GenomeWeb

BiOasis Technologies

Provista Diagnostics has formed its scientific advisory board, appointing Karen Anderson, Carlos Arteaga, Robert Benezra, Andrew Dannenberg, and Joshua LaBaer.

The figure comes from a report commissioned by proteomics firm Proteome Sciences, which, like a number of other protein biomarker firms including Quanterix, Rules-Based Medicine, and NextGen Sciences, has made AD a significant focus of its R&D and commercialization efforts.

The assay, which uses SISCAPA MRM-MS to measure serum levels of melanotransferrin – a protein that a number of studies have tied to Alzheimer's – marks an example of mass spec-based proteomics' ongoing move into the clinical setting.

The latest pact will focus on the use of p97 as a delivery system to transport Alzheimer's drugs across the blood-brain barrier. Last month, Bioasis and UBC inked a first research collaboration to develop and test a p97-based blood test to diagnose and monitor Alzheimer's.

The Canadian firm will use the funds to support further development of its diagnostic assays for Alzheimer's disease.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.